SkinBioTherapeutics PLC
LSE:SBTX

Watchlist Manager
SkinBioTherapeutics PLC Logo
SkinBioTherapeutics PLC
LSE:SBTX
Watchlist
Price: 15.125 GBX -9.02% Market Closed
Market Cap: 39.1m GBX

Wall Street
Price Targets

SBTX Price Targets Summary
SkinBioTherapeutics PLC

Wall Street analysts forecast SBTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SBTX is 29.58 GBX with a low forecast of 29.29 GBX and a high forecast of 30.45 GBX.

Lowest
Price Target
29.29 GBX
94% Upside
Average
Price Target
29.58 GBX
96% Upside
Highest
Price Target
30.45 GBX
101% Upside
SkinBioTherapeutics PLC Competitors:
Price Targets
0HS8
Caladrius Biosciences Inc
526% Upside
300685
Amoy Diagnostics Co Ltd
32% Upside
PBYI
Puma Biotechnology Inc
10% Downside
2616
CStone Pharmaceuticals
146% Upside
2171
CARsgen Therapeutics Holdings Ltd
27% Upside
STRO
Sutro Biopharma Inc
351% Upside
REGN
Regeneron Pharmaceuticals Inc
11% Upside
NTRA
Natera Inc
3% Downside

Revenue
Forecast

Revenue Estimate
SkinBioTherapeutics PLC

The compound annual growth rate of SkinBioTherapeutics PLC's revenue for the next 3 years is 90%.

N/A
Past Growth
90%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
SkinBioTherapeutics PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss

Net Income
Forecast

Net Income Estimate
SkinBioTherapeutics PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-42%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SBTX's stock price target?
Price Target
29.58 GBX

According to Wall Street analysts, the average 1-year price target for SBTX is 29.58 GBX with a low forecast of 29.29 GBX and a high forecast of 30.45 GBX.

What is SkinBioTherapeutics PLC's Revenue forecast?
Projected CAGR
90%

The compound annual growth rate of SkinBioTherapeutics PLC's revenue for the next 3 years is 90%.

Back to Top